The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected. METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016. RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups. CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“From the first landmark 1967 Veterans Administration Cooperative Study2 to the 2021 SPRINT trial3, all outcome trials in hypertension have used the average of snapshot BP levels to demonstrate the efficacy of antihypertensive drug therapy in reducing cardiovascular events.”
From Blood pressure and its variability: classic and novel measurement techniques (2022) · cites this paper as [3]
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationA Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Chugh, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmx170008 · Cited by 2,413
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
Appel, L. J., Wright, J. T., Greene, T., Agodoa, L. Y., Astor, B. C., Bakris, G. L., Cleveland, W. H., Charleston, J., Contreras, G., Faulkner, M. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910975 · Cited by 719
Ambrosius, W. T., Sink, K. M., Foy, C. G., Berlowitz, D. R., Cheung, A. K., Cushman, W. C., Fine, L. J., Goff, D. C., Johnson, K. C., Killeen, A. A., et al. (2014) · Clinical Trials · doi:10.1177/1740774514537404 · Cited by 544
Cited by
The Global Burden of Cardiovascular Diseases and Risk
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.005 · Cited by 2,217
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., Yang, J., Jiang, Y., Xu, X., Wang, T.-D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111437 · Cited by 784
Treatment of hypertension: a review
Carey, R. M., Moran, A. E., & Whelton, P. K. (2022) · JAMA · doi:10.1001/jama.2022.19590 · Cited by 455
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-20
- Volume
- 384
- Issue
- 20
- Pages
- 1921-1930
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9907774
- OpenAlex
- W3161638097
- Cited by
- 454
- References
- 20
- Citations by year
- 2026: 74 · 2025: 92 · 2024: 74 · 2023: 83 · 2022: 105 · 2021: 26
- FWCI
- 48.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health, National Heart, Lung, and Blood Institute
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
- NIH, National Institute on Aging
- NIH, National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, major adverse cardiovascular events, all-cause mortality, cardiovascular risk, adverse events, acute kidney injury, heart failure, post-trial follow-up, SPRINT trial, acute coronary syndrome, stroke, myocardial infarction, syncope, electrolyte imbalance, hypotension
- MeSH terms
- Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. https://app.cochat.ai/papers/10.1056/nejmoa1901281
- The paper
- The SPRINT Research Group. (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1901281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.